Entry into a Material Definitive Agreement

National Healthcare Properties, Inc. — Form 8-K summary

Reporting and event dates: The report identifies November 4, 2026 as the date of the earliest event reported. It describes a share repurchase authorization on that date and an ATM equity sales agreement entered into on November 10, 2026; the report was signed November 10, 2026. This is a material-events filing, not a periodic financial report.

Capital actions and key terms

  • ATM offering: The company and its operating partnership may offer and sell common stock for aggregate gross proceeds of up to $300 million through an agreement with multiple agents. Sales are optional and may occur in market transactions, negotiated transactions, or other permitted methods.
  • Forward sales: The company may enter into forward sale agreements. It expects to settle any such agreements physically, which would generate cash based on the shares settled and the applicable forward sale price. It may instead elect cash or net-share settlement; those alternatives may provide no proceeds and could require cash or shares from the company. The company receives no initial proceeds from the sale of borrowed shares used to hedge a forward agreement.
  • Fees: Agents may receive commissions of up to 2.0% on shares sold as the company’s sales agent. For forward sales, the commission may be reflected as a reduction to the initial forward sale price, at a mutually agreed rate of up to 2.0%. Principal sales may have a separately agreed commission or discount that could exceed 2.0%.
  • Use of proceeds: Net proceeds, if any, from ATM sales or physical settlement of forward agreements are intended for general corporate purposes, including property acquisitions and working capital.
  • Share repurchase authorization: The board authorized repurchases of up to $100 million of outstanding common stock. Repurchases may be made through open-market transactions, block trades, or other methods designed to comply with Rule 10b-18. The program does not require any purchases and may be changed, suspended, or terminated by the board at any time.

Financial results and comparison

The filing does not provide revenue, profit, cash flow, margins, debt balances, liquidity measures, or other operating results, and it does not compare financial performance with a prior period. It notes existing credit facilities of $750 million for a senior unsecured revolving facility, $300 million for a senior unsecured term loan, and $150 million for a senior unsecured delayed-draw term loan; it does not state amounts drawn or available.

Investor considerations

  • The ATM could raise capital for acquisitions and working capital but may dilute existing shareholders if shares are issued. No specific sale amount, timing, or price is committed.
  • The repurchase program could offset some share issuance but is discretionary; the filing does not say that repurchases will occur or how they will be funded.
  • Forward-sale proceeds depend on the terms and settlement of any agreements entered into. Cash or net-share settlement could result in no proceeds, and cash settlement could require a payment.
  • Affiliates of certain agents are lenders under the company’s credit facilities. The filing provides no further discussion of any resulting conflicts or their management.
  • The company and operating partnership provided customary representations and indemnities, including for certain securities-law liabilities.

Important facts to verify

  • Whether ATM sales or forward agreements are executed, and the actual proceeds, pricing, fees, and settlement choices.
  • Shares issued under the program and the resulting dilution, alongside any shares repurchased and their cost.
  • Credit-facility balances, availability, covenants, and the intended funding mix for acquisitions and working capital.
  • The precise timing and relationship between the November 4 repurchase authorization and the November 10 ATM agreement, as the filing describes events on both dates.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.